Michael J Manyak

Author:

Michael J. Manyak

ISBN #:

0881678783

US Patent:

6335321, Jan 1, 2002

Filed:

Apr 21, 2000

Appl. No.:

09/556468

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

Assignee:

The George Washington University Medical Center - Washington DC

International Classification:

A61K 3800

US Classification:

514 21, 514 12

Abstract:

The invention relates to methods for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relates to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A.

US Patent:

6358915, Mar 19, 2002

Filed:

Dec 9, 1997

Appl. No.:

08/987502

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

Assignee:

George Washington University - Washington DC

International Classification:

A61K 3800

US Classification:

514 2, 514 45, 514 12, 514 15, 436501, 530350, 536 235

Abstract:

The invention relates to methods for determining degree of integrin-mediated maintenance of cell invasive capacity of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine degree of integrin-mediated maintenance of cell invasive capacity of epithelial derived tumors, particularly prostatic, breast, and lung cancers. In these regards, the invention relates to determining protein or mRNA of effectors of integrin-mediated maintenance of cell invasive capacity, particularly uteroglobin protein or mRNA, or to gauge degree of integrin-mediated maintenance of cell invasive capacity of prostatic, breast, or lung tumors. The invention also relates to methods and compositions, such as uteroglobin, which specifically bind to integrin and are effectors of integrin-mediated maintenance of tumor cell invasive capacity and thus inhibit metastasis.

US Patent:

6395715, May 28, 2002

Filed:

Apr 21, 2000

Appl. No.:

09/556467

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

Assignee:

The George Washington University Medical Center - Washington DC

International Classification:

A01N 4304

US Classification:

514 44, 424 932, 4353201

Abstract:

The present invention provides a novel method for inhibiting the growth of tumor cells of epithelial origin, comprising administration of a functional uteroglobin gene in a gene therapy regime, so as to inhibit growth of the tumor cells.

US Patent:

6509316, Jan 21, 2003

Filed:

Dec 9, 1997

Appl. No.:

08/987505

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

Assignee:

George Washington University - Washington DC

International Classification:

A61K 3514

US Classification:

514 12, 514 21, 530350, 530352, 530386, 530850, 530851, 530853

Abstract:

The present invention relates to pharmaceutical compositions, methods and kits that provide for the early diagnosis and treatment of lung cancer. More particularly, the present invention relates to pharmaceutical compositions containing uteroglobin for preventing or inhibiting metastasis of lung tumor cells and methods of using the same to prevent or inhibit metastasis of lung tumor cells. The present invention also relates to methods and kits for early diagnosis of metastatic lung cancer by assaying for uteroglobin and comparing the results against control cells. The present invention also relates to methods and kits for detection of metastatic lung cancer by assaying for the presence of an aberrant form of uteroglobin.

US Patent:

20020151470, Oct 17, 2002

Filed:

Jan 23, 2002

Appl. No.:

10/052498

Inventors:

Steven Patierno - Falls Church VA, US
Michael Manyak - Chevy Chase MD, US

Assignee:

The George Washington University Medical Center

International Classification:

A61K038/41
A61K031/405

US Classification:

514/006000, 514/420000

Abstract:

The invention relates to methods for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relates to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. More particularly in this regard, the invention relates to uteroglobin or muteins, peptide analogs or mimetics of uteroglobin and lipocortins or muteins, peptide analogs, or mimetics of lipocortins that inhibit metastasis. Especially it relates to methods and compositions in which uteroglobins, particularly human uteroglobins, inhibit or prevent metastasis of cancer, particularly prostatic cancer.

US Patent:

6288039, Sep 11, 2001

Filed:

Dec 9, 1997

Appl. No.:

8/987506

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

Assignee:

George Washington University - Washington DC

International Classification:

G01N 3348
A61K 3800
A61K 3816

US Classification:

514 21

Abstract:

The present invention relates to pharmaceutical compositions, methods and kits that provide for the early diagnosis and treatment of breast cancer. More particularly, the present invention relates to pharmaceutical compositions containing uteroglobin for preventing or inhibiting metastasis of breast tumor cells and methods of using the same to prevent or inhibit metastasis of breast tumor cells. The present invention also relates to methods and kits for early diagnosis of metastatic breast cancer by assaying for uteroglobin and comparing the results against control cells. The present invention also relates to methods and kits for detection of metastatic breast cancer by assaying for the presence of an aberrant form of uteroglobin.

US Patent:

59358602, Aug 10, 1999

Filed:

Jun 5, 1996

Appl. No.:

8/658796

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

Assignee:

The George Washington University - Washington DC

International Classification:

G01N 3348

US Classification:

436 64

Abstract:

The invention relates to methods for identifying prostatic intraepithelial neoplasia by determining the uteroglobin concentration in a tissue sample.

US Patent:

63164167, Nov 13, 2001

Filed:

Feb 25, 2000

Appl. No.:

9/512385

Inventors:

Steven R. Patierno - Falls Church VA
Michael J. Manyak - Chevy Chase MD

International Classification:

A61K 3800
A61K 3816

US Classification:

514 21

Abstract:

The invention relates to method for identifying prostatic intraepithelial neoplasia, methods for determining metastatic potential of tumors, and to methods and compositions for inhibiting or preventing metastasis of cancers. In one aspect, the invention provides a method to determine metastatic potential of tumors, particularly prostatic tumors. In another aspect, the invention provides a method of identifying prostate cancer associated conditions, particularly prostatic intraepithelial neoplasia. In these regards, the invention relate to determining protein or mRNA of effectors of arachidonic acid release, particularly uteroglobin protein or mRNA, to identify intermediate conditions such as PIN or to gauge metastatic potential of prostatic tumors. The invention also relates to methods and compositions that prevent or inhibit metastasis of cancers. In this regard, the invention particularly relates to methods and compositions that inhibit arachidonic acid, those that inhibit phospholipase A. sub. 2.